INBIOGEN Co., Ltd.

KOSE:A101140 Stock Report

Market Cap: ₩67.4b

INBIOGEN Past Earnings Performance

Past criteria checks 0/6

INBIOGEN's earnings have been declining at an average annual rate of -1.9%, while the Luxury industry saw earnings growing at 18.9% annually. Revenues have been declining at an average rate of 9.4% per year.

Key information

-1.9%

Earnings growth rate

-6.4%

EPS growth rate

Luxury Industry Growth21.6%
Revenue growth rate-9.4%
Return on equity-4.4%
Net Margin-101.4%
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In Growth

Jan 17
Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In Growth

Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?

Mar 26
Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?

Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five Years

Jan 31
Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five Years

Revenue & Expenses Breakdown

How INBIOGEN makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSE:A101140 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,436-6,5244,95824
30 Jun 245,483-1,3085,25821
31 Mar 245,7175,9485,26114
31 Dec 236,24111,8595,7398
30 Sep 236,17437,3376,3712
30 Jun 237,59429,4656,6392
31 Mar 239,394-54,4196,8693
31 Dec 2210,420-116,9496,5214
30 Sep 2212,796-17,5407,9256
30 Jun 2212,585-25,6638,12923
31 Mar 2211,6984,3068,32126
31 Dec 2110,48194,1258,70025
30 Sep 219,029-55,1067,53122
30 Jun 219,965-45,4216,8875
31 Mar 2110,518-2,1906,0440
31 Dec 2010,218-45,0785,4920
30 Sep 2010,384-20,7514,2640
30 Jun 2011,2561033,8300
31 Mar 2010,52112,2173,2850
31 Dec 199,79513,1242,3930
30 Sep 198,87319,9661,7430
30 Jun 196,7537,368-4460
31 Mar 196,3451,536-6630
31 Dec 187,5661,664-7900
30 Sep 186,8362,060-2580
30 Jun 186,665-8271,3810
31 Mar 185,999-1,1321,7440
31 Dec 177,077-1,2111,8830
30 Sep 178,347-1,5182,4770
30 Jun 178,134-1,9172,5780
31 Mar 179,678-2,0372,6490
31 Dec 1611,545-2,2563,2070
30 Sep 1611,970-2,3682,3980
30 Jun 1611,436-5,5545,0920
31 Mar 1610,064-5,6174,7600
31 Dec 158,865-5,6864,5400
30 Sep 158,862-5,0034,75021
30 Jun 1510,955-4,3575,0781
31 Mar 1511,674-1,7172,73921
31 Dec 1411,762-1,6122,79421
30 Sep 1411,413-2,0042,9949
30 Jun 149,648-2,0513,04120
31 Mar 149,719-1,4472,7179

Quality Earnings: A101140 is currently unprofitable.

Growing Profit Margin: A101140 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A101140 is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.

Accelerating Growth: Unable to compare A101140's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A101140 is unprofitable, making it difficult to compare its past year earnings growth to the Luxury industry (-26.8%).

Return on Equity

High ROE: A101140 has a negative Return on Equity (-4.35%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/17 23:42
End of Day Share Price 2025/01/17 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

INBIOGEN Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution